Developing a robust ultrafiltration-LC-MS/MS method for quantitative analysis of unbound vadimezan (ASA404) in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 21, 2011, Pages 1927-1933

  Li, Wenkui ^a   Lin, Hui ^a   Smith, Harold T ^a   Tse, Francis L S ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

ASA404; Incurred sample reanalysis; Incurred sample stability; Nonspecific binding; Stability; Ultrafiltration; Unbound analyte; Vadimezan

Indexed keywords

ANALYTES; ASA404; INCURRED SAMPLE STABILITY; NONSPECIFIC BINDING; REANALYSIS; VADIMEZAN;

CALIBRATION; CENTRIFUGATION; CENTRIFUGES; LAKES; PLASMA (HUMAN); PLASMAS; QUALITY CONTROL; ULTRAFILTRATION;

PLASMA STABILITY;

VADIMEZAN;

ACCURACY; ARTICLE; CALIBRATION; CENTRIFUGATION; CONTROLLED STUDY; FREEZE THAWING; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; ROOM TEMPERATURE; TEMPERATURE SENSITIVITY; ULTRAFILTRATION; VALIDATION PROCESS;

CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HUMANS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; ULTRAFILTRATION; XANTHONES;

EID: 79959357085     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.05.012     Document Type: Article

References (20)

1. Sparreboom A., Nooter K., Loos W.J., Verweij J. The Netherlands J. Med. 2001, 59:196.
2. Schuhmacher J., Buhner K., Witt-Laido A. J. Pharm. Sci. 2000, 89:1008.
3. Nowak I., Shaw L.M. Clin. Chem. 1995, 41:1011.
4. Cohen L. Plasma protein-binding methods in drug discovery. Optimization in Drug Discovery (Methods in Pharmacology and Toxicology) 2004, 111-122. Human Press. Z. Yan, G.W. Caldwell (Eds.).
5. Lee K.J., Mower R., Hollenbeck T., Castelo J., Johnson N., Gordon P., Sinko P.J., Holme K., Lee Y.H. Pharm. Res. 2003, 2003:1015.
6. Mortier K.A., Lambert W.E. J. Chromatogr. A 2006, 1108:195.
7. Gardner E.R., Dahut W., Figg W.D. J. Chromatogr. B 2008, 862:213.
8. Shen B., Li S., Zhang Y., Yuan X., Fan Y., Liu Z., Hu Q., Yu X. J. Pharm. Biomed. Anal. 2009, 50:515.
9. Patel C.G., Mendonza A.E., Akhlaghi F., Majid O., Trull A.K., Lee T., Holt D.W. J. Chromatogr. B 2004, 813:287.
10. Lee J.W., Petersen M.E., Lin P., Dressler D., Bekersky I. Ther. Drug Monit. 2001, 23:268.
11. Baguley B.C., Siemann D.W. Expert Opin. Investig. Drugs 2010, 19:1413.
12. McKeage M.J., Baguley B.C. Cancer 2010, 116:1859.
13. Head M., Jameson M.B. Expert Opin. Investig. Drugs 2010, 19:295.
14. Zhou S., Paxton J.W., Kestell P., Tingle M.D. J. Pharm. Pharmacol. 2001, 53:463.
15. Zhou S., Paxton J.W., Tingle M.D., Kestell P. J. Chromatogr. B 2001, 757:359.
16. Bowers W.F., Fulton S., Thompson J. Clin. Pharmacokinet. 1984, 9:49.
17. Whitlam J.B., Brown E.F. J. Pharm. Sci. 1981, 70:146.
18. Zhang J., Musson D.G. J. Chromatogr. B 2006, 843:47.
19. Ekins R. Clin. Chem. 1992, 38:1289.
20. Kwong T.C. Clin. Chim. Acta 1985, 151:193.